CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for
colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea …

Chemotherapy-induced diarrhoea : Current Opinion in Supportive and Palliative Care
Chemotherapy-induced diarrhoea : Current Opinion in Supportive and Palliative Care Log in or …

Chemotherapy-induced diarrhoea (CID) is a common side-effect experienced by patients
being treated with a variety of antineoplastic agents. Approximately 80% of patients …

Objective. Delayed-type diarrhea is a common side effect of irinotecan and is associated
with a bacterial-mediated formation of the active irinotecan metabolite SN-38 from its …

Purpose: An antitumor camptothecin derivative CPT-11 has proven a broad spectrum of
solid tumor malignancy, but its severe diarrhea has often limited its more widespread use …

Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea
associated with protracted irinotecan administration may reduce morbidity and improve dose …

Background We performed a prospective study to evaluate the efficacy of activated charcoal
(AC) to prevent irinotecan‐induced diarrhea (IID). Procedure We designed a prospective …

Objectives The effect of genistein, a natural soy isoflavone, on pharmacokinetics and
intestinal toxicity, or late-onset diarrhoea, of irinotecan hydrochloride (CPT-11) was …

Diarrhea is a common complication in the cancer population, occurring in 5-10% of patients
with advanced disease. Women are more likely to have diarrhea than men after excluding …

BACKGROUND: Ticlopidine hydrochloride-induced liver abnormalities have been reported
in the world. In Japan, the five-year (1995–2000) spontaneous serious reports of ticlopidine …